- McKesson shares surged about 16.3% at the close and roughly 16.5% after hours after the company raised its full-year earnings outlook following a strong quarterly beat.
- Analysts reacted positively, with TD Cowen lifting its price target to $1,012 and reiterating a Buy rating, while other firms maintained cautious optimism.
- The rally stood out against a broader market sell-off, as traders now focus on upcoming catalysts including the medical-surgical unit separation and future earnings updates.
Shares of McKesson Corporation (NYSE: MCK) rallied sharply in the most recent trading session following a bullish update tied to its quarterly financials and full-year outlook, leaving market participants to reassess positioning after a broader market slump. In an otherwise risk-off environment for equities, McKesson’s stock closed the regular session with significant gains and extended those moves in after-hours trading.
On Thursday, February 5, 2026, McKesson’s stock climbed approximately +16.3% by the market close, with shares trading around $956.61, up roughly $133.76 from the prior session’s level on strong volume and heightened optimism around the company’s guidance and segment performance. The rally carried into after-hours trading with gains of roughly +16.5%, as investors reacted to the company’s raised profit expectations and investors evaluated recent analyst commentary.(RTTnews)
The catalyst for McKesson’s sharp upward move was its quarterly earnings release showing an adjusted earnings per share beat and raised full-year guidance. According to earnings coverage and press summaries, McKesson reported EPS and revenue above consensus expectations for its third fiscal quarter, while the company also lifted its fiscal 2026 adjusted EPS outlook to a new range of roughly $38.80 to $39.20, signaling stronger underlying profitability momentum in specialty drug distribution and other high-margin segments.(marketbear)
Analysts responded swiftly to these updates. TD Cowen reiterated its Buy rating and increased its price target on McKesson shares from $1,000 to $1,012, underscoring confidence in McKesson’s growth drivers and solid execution amid strategic shifts. Other brokerages have also nudged targets higher; for example, Wells Fargo recently modestly raised its price target to $925 while maintaining an Equal-Weight rating, reflecting a nuanced but broadly positive sentiment across the sell-side.(gurufocus)
This McKesson outperformance stands in contrast to the broader U.S. equity market’s weakness on February 5, 2026. Major benchmarks such as the S&P 500 and Nasdaq Composite both declined as investors grappled with a tech sector sell-off and concerns about labor market signals and excessive AI-related spending, with indices sliding by roughly 1.2%–1.6% on the session. The Dow Jones Industrial Average also saw notable weakness, contributing to a broadly cautious risk appetite among traders.(APnews)
Despite this macro pressure, McKesson’s stock has drawn attention as a potential defensive yet growth-oriented play within the healthcare distribution and services sector, with many traders highlighting the resilience of its specialty drug distribution and biopharma services franchises. Commentary from market analysts emphasizes not only the near-term earnings beat but also strategic catalysts such as margin stabilization, growth in high-value segments, and progress on the planned medical-surgical separation as possible nodes for further valuation expansion.